Ipsen’s Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead’s Livdelzi
Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset. Exton, PA.,